Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829276) titled 'Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia' on Sept. 14.

Study Type: Observational

Primary Sponsor: Zhejiang Provincial People's Hospital

Condition: Malignant Tumor

Recruitment Status: Recruiting

Date of First Enrollment: November 1, 2026

Target Sample Size: 350

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07829276

Disclaimer: Curated by HT Syndication....